Related Experiment Video
Updated: Aug 29, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
[Comparative analysis of associated live viral vaccines against measles and mumps]
Insights
This study evaluated a new Russian mumps-measles vaccine and the Priorix trivaccine. Both vaccines demonstrated low reactogenicity and high immunogenicity in infants, children, and adolescents.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- The development of effective combination vaccines is crucial for public health.
- Assessing vaccine safety and immunogenicity across different age groups is essential.
Purpose of the Study:
- To evaluate the reactogenicity and immunogenicity of a new Russian live-associated mumps-measles vaccine.
- To assess the live trivaccine (measles-mumps-rubella) "Priorix" in various age cohorts.
Main Methods:
- Follow-up study involving 139 infants (12-18 months).
- Follow-up study involving 122 children (6-7 years).
- Follow-up study involving 129 adolescents (18-10 years).
Main Results:
- The new Russian mumps-measles vaccine showed low reactogenicity.
- The Priorix trivaccine demonstrated high immunogenicity.
- Both combined vaccines were well-tolerated and effective across all studied age groups.
Conclusions:
- The evaluated combined vaccines are safe and effective for immunization.
- These vaccines represent valuable tools for controlling measles, mumps, and rubella.
- Further research can explore long-term efficacy and broader population studies.
Abstract:
Vaccinations and revaccinations by a new Russian live associated mumps-measles vaccine and by a live trivaccine (measies-mumps-rubella)--"Priorix--were performed. We followed up 139 infants vaccinated at an age of 12-18 months, 122 children vaccinated at an age of 6-7 years and 129 persons vaccinated at an age of 18-10 years. The combined vaccines were found to be low reactogenic and high immunogenic preparations.
Related Concept Videos
Poliomyelitis
Vaccinations
Vaccines
Viral Meningitis
Smallpox
Chickenpox

